pyrroles has been researched along with Carcinoma, Neuroendocrine in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 20 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abe, T; Hashimoto, R; Igarashi, H; Inoue, K; Ito, T; Karashima, T; Kawabe, K; Miki, M; Ogawa, Y; Ohishi, Y; Yamasaki, I | 1 |
| Atkins, J; Busaidy, N; Fu, S; Hong, D; Kurzrock, R; Naing, A; Sherman, S; Wheler, J | 1 |
| Baudin, E; Borson-Chazot, F; Hescot, S; Lombès, M | 1 |
| Baudin, E; Bonichon, F; Borget, I; Brassard, M; Chougnet, CN; Claude-Desroches, M; de la Fouchardière, C; Do Cao, C; Giraudet, AL; Leboulleux, S; Massicotte, MH; Schlumberger, M | 1 |
| Bugalho, MJ; Marques, P; Vieira, Mda S | 1 |
| Covell, LL; Ganti, AK | 1 |
| Bandaru, S; Dunna, NR; Girdhar, A; Hussain, T; Kandula, V; Nayarisseri, A; Pudutha, A | 1 |
| Gardner, EE; Rudin, CM | 1 |
| Becher-Boveleth, N; Broecker-Preuss, M; Mann, K | 1 |
| Gómez-Sáez, JM | 1 |
| Gilabert, M; Kavan, P; Rho, YS | 1 |
| Bagheri-Yarmand, R; Gagel, RF; Grubbs, EG; Williams, MD | 1 |
| Asselineau, J; Bournaud-Salinas, C; Caron, P; Catargi, B; Daste, A; de la Fouchardière, C; Delord, JP; Digue, L; Do Cao, C; Doussau, A; Gimbert, A; Klein, M; Nicolli-Sire, P; Pedenon, D; Picat, MQ; Pouessel, D; Ravaud, A; Rodien, P; Wemeau, JL | 1 |
| Bodei, L; Cinieri, S; de Braud, F; Delle Fave, G; Fazio, N; Lorizzo, K; Maiello, E; Orlando, L; Paganelli, G; Spada, F; Squadroni, M | 1 |
| Liakakos, T; Roukos, DH | 1 |
| Benavent, M; de Miguel, MJ; Garcia-Carbonero, R | 1 |
| Chiu, J; Cho, WY; Lang, B; Leung, R; Shek, T; Wong, H; Yat, WK; Yau, LC; Yau, T | 1 |
| Lin, CI; Lorch, JH; Ruan, DT; Whang, EE | 1 |
| Ahmadzadeh, A; Babaei, M; Elahi, F; Hassanpour, K; Yadollahzadeh, M | 1 |
7 review(s) available for pyrroles and Carcinoma, Neuroendocrine
| Article | Year |
|---|---|
[Targeted therapies, prognostic and predictive factors in endocrine oncology].
Topics: Antineoplastic Agents; Carcinoma, Neuroendocrine; Clinical Trials, Phase III as Topic; Disease-Free Survival; Endocrine Gland Neoplasms; Everolimus; Humans; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Piperidines; Prognosis; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib; Thyroid Neoplasms; Treatment Outcome | 2013 |
Treatment of advanced thyroid cancer: role of molecularly targeted therapies.
Topics: Anilides; Antineoplastic Agents; Axitinib; Carcinoma, Neuroendocrine; DNA Mutational Analysis; Drug Approval; Humans; Imidazoles; Indazoles; Indoles; MAP Kinase Signaling System; Molecular Targeted Therapy; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Piperidines; Proto-Oncogene Proteins c-ret; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Sorafenib; Sulfonamides; Sunitinib; Thyroid Neoplasms; United States; United States Food and Drug Administration; Vascular Endothelial Growth Factor A | 2015 |
Sunitinib for the treatment of thyroid cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Neuroendocrine; Disease-Free Survival; Humans; Indoles; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Thyroid Neoplasms | 2016 |
Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Neuroendocrine; Everolimus; Humans; Indoles; Molecular Targeted Therapy; Pancreatic Neoplasms; Pyrroles; Receptors, Somatostatin; Sirolimus; Somatostatin; Sunitinib; Vascular Endothelial Growth Factor A | 2010 |
New targeted agents in gastroenteropancreatic neuroendocrine tumors.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Clinical Trials as Topic; Everolimus; Gastrointestinal Neoplasms; Humans; Indoles; Molecular Targeted Therapy; Neovascularization, Pathologic; Pancreatic Neoplasms; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases | 2012 |
Sunitinib and pancreatic neuroendocrine tumours. More assessment needed.
Topics: Antineoplastic Agents; Carcinoma, Neuroendocrine; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Indoles; Pancreatic Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Sunitinib | 2012 |
Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy.
Topics: Antineoplastic Agents; Carcinoma, Neuroendocrine; Everolimus; Gene Expression Regulation, Neoplastic; Humans; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrroles; Radiopharmaceuticals; Signal Transduction; Sirolimus; Somatostatin; Sunitinib; TOR Serine-Threonine Kinases | 2013 |
2 trial(s) available for pyrroles and Carcinoma, Neuroendocrine
| Article | Year |
|---|---|
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carcinoembryonic Antigen; Carcinoma, Neuroendocrine; Disease Progression; Female; Humans; Indoles; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-ret; Pyridines; Pyrroles; Quinolines; Quinolones; Retrospective Studies; Sorafenib; Sunitinib; Thyroid Neoplasms; Treatment Outcome; Valproic Acid | 2013 |
A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study.
Topics: Adenocarcinoma, Follicular; Adult; Aged; Angiogenesis Inhibitors; Bone Neoplasms; Carcinoma; Carcinoma, Neuroendocrine; Carcinoma, Papillary; Female; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neck; Pyrroles; Sunitinib; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Treatment Outcome | 2017 |
11 other study(ies) available for pyrroles and Carcinoma, Neuroendocrine
| Article | Year |
|---|---|
An Advanced Well-differentiated Pancreatic Neuroendocrine Carcinoma (NET-G3) Associated with Von Hippel-Lindau Disease.
Topics: Antineoplastic Agents; Asian People; Carcinoma, Neuroendocrine; Everolimus; Female; Humans; Indoles; Liver Neoplasms; Middle Aged; Pancreatic Neoplasms; Pyrroles; Sunitinib; Treatment Outcome; von Hippel-Lindau Disease | 2018 |
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.
Topics: Adenocarcinoma; Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma; Carcinoma, Neuroendocrine; Carcinoma, Papillary; Disease-Free Survival; Female; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Piperidines; Pleural Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Treatment Outcome | 2014 |
Ectopic cushing in a patient with medullary thyroid carcinoma: hypercortisolism control and tumor reduction with Sunitinib.
Topics: ACTH Syndrome, Ectopic; Adrenocortical Hyperfunction; Antineoplastic Agents; Carcinoma, Neuroendocrine; Humans; Indoles; Male; Middle Aged; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Thyroid Neoplasms | 2015 |
High Affinity Pharmacological Profiling of Dual Inhibitors Targeting RET and VEGFR2 in Inhibition of Kinase and Angiogeneis Events in Medullary Thyroid Carcinoma.
Topics: Angiogenesis Inhibitors; Anilides; Carcinoma, Neuroendocrine; Databases, Chemical; Drug Discovery; Humans; Imidazoles; Indoles; Molecular Docking Simulation; Molecular Structure; Niacinamide; Oligonucleotides; Piperidines; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sunitinib; Thyroid Neoplasms; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Drug therapy: Preclinical oncology - reporting transparency needed.
Topics: Animals; Antineoplastic Agents; Carcinoma, Neuroendocrine; Carcinoma, Renal Cell; Clinical Trials as Topic; Evidence-Based Medicine; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Medical Oncology; Meta-Analysis as Topic; Neoplasms; Pancreatic Neoplasms; Practice Guidelines as Topic; Pyrroles; Research Design; Research Report; Stomach Neoplasms; Sunitinib; Treatment Outcome | 2016 |
Cell Death Induction by the Indirubin Derivative 7BIO and the BH3 Mimetic Drugs ABT-737 and GX15-070 in Medullary Thyroid Carcinoma Cells.
Topics: BH3 Interacting Domain Death Agonist Protein; Biphenyl Compounds; Carcinoma, Neuroendocrine; Cell Death; Cell Line, Tumor; Humans; Indoles; Molecular Mimicry; Nitrophenols; Piperazines; Protein Kinase Inhibitors; Pyrroles; Sulfonamides; Thyroid Neoplasms | 2016 |
Targeted Therapies Provide Treatment Options for Poorly Differentiated Pancreatic Neuroendocrine Carcinomas.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Neuroendocrine; Cell Differentiation; Everolimus; Female; Humans; Indoles; Male; Middle Aged; Molecular Targeted Therapy; Pancreatic Neoplasms; Pyrroles; Sunitinib; TOR Serine-Threonine Kinases | 2017 |
ATF4 Targets RET for Degradation and Is a Candidate Tumor Suppressor Gene in Medullary Thyroid Cancer.
Topics: Activating Transcription Factor 4; Adolescent; Adult; Aged; Aged, 80 and over; Anilides; Animals; Apoptosis; Blotting, Western; Carcinoma, Neuroendocrine; Cell Proliferation; Cell Survival; Female; Genes, Tumor Suppressor; HEK293 Cells; Humans; Immunohistochemistry; Indoles; Kaplan-Meier Estimate; Male; Mice; Mice, Knockout; Middle Aged; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Pyridines; Pyrroles; Real-Time Polymerase Chain Reaction; Sunitinib; Thyroid Gland; Thyroid Neoplasms; Ubiquitination; Young Adult | 2017 |
Everolimus and sunitinib: from mouse models to treatment of pancreatic neuroendocrine tumors.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Neuroendocrine; Disease Models, Animal; Everolimus; Humans; Indoles; Mice; Pancreatic Neoplasms; Pyrroles; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases | 2011 |
Autophagic activation potentiates the antiproliferative effects of tyrosine kinase inhibitors in medullary thyroid cancer.
Topics: Antineoplastic Agents; Autophagy; Benzenesulfonates; Benzimidazoles; Carcinoma, Neuroendocrine; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Everolimus; Humans; Immunosuppressive Agents; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-ret; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Thyroid Neoplasms | 2012 |
Neuroendocrine tumor of the gallbladder.
Topics: Antineoplastic Agents; Carcinoma, Neuroendocrine; Catheter Ablation; Cisplatin; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Female; Gallbladder; Gallbladder Neoplasms; Gemcitabine; Humans; Indoles; Middle Aged; Pyrroles; Sunitinib; Taxoids; Ultrasonography | 2013 |